December 16, 2021 12:35 PM EST
Manufacturing

Buoyed by semaglu­tide suc­cess, No­vo Nordisk un­corks plans for $2.58B man­u­fac­tur­ing ex­pan­sion in Den­mark

Kyle Blankenship

No­vo Nordisk scored a pair of dou­ble wins the last cou­ple years with the ap­proval of two dif­fer­ent forms of semaglu­tide, the com­pa­ny’s newest block­buster …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times